Tenascins: regulation and putative functions during pathological stress

Bourdon MA, 1983, Human glioma‐mesenchymal extracellular matrix antigen defined by monoclonal antibody, Cancer Res, 43, 2796

10.1083/jcb.98.6.1937

10.1016/0092-8674(88)90158-4

10.1016/S0021-9258(18)98545-5

10.1006/excr.2000.5041

10.1007/BF01921736

10.1016/S0945-053X(00)00106-2

10.1016/S0079-6123(01)32069-1

10.1016/S0945-053X(00)00136-0

10.1083/jcb.122.1.265

10.1046/j.1432-1327.1999.00563.x

10.1083/jcb.125.2.483

10.1002/aja.1002030411

10.1083/jcb.134.6.1499

10.1006/excr.1999.4658

10.1002/(SICI)1097-4695(199804)35:1<1::AID-NEU1>3.0.CO;2-9

10.1073/pnas.86.17.6582

10.1128/MCB.12.5.2124

10.1159/000019099

10.1093/hmg/11.21.2581

10.1038/ng0997-104

10.1172/JCI12881

10.1056/NEJMoa002939

10.1038/ng850

10.1359/jbmr.2002.17.7.1180

10.1159/000063713

10.1016/S0014-5793(01)02361-4

10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.0.CO;2-G

10.1242/jcs.106.2.597

10.1083/jcb.109.4.1795

10.1002/jnr.1055

10.1523/JNEUROSCI.18-16-06218.1998

10.1074/jbc.M010210200

10.1016/0012-1606(90)90256-I

10.1038/307364a0

10.1016/0012-1606(88)90252-7

10.1016/0092-8674(86)90374-0

Huang W, 2001, Interference of tenascin‐C with syndecan‐4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation, Cancer Res, 61, 8586

10.1242/jcs.95.2.263

10.1073/pnas.96.6.2805

10.1016/S0021-9258(20)89510-6

10.1074/jbc.272.24.15501

10.1083/jcb.115.4.1127

10.1242/jcs.110.13.1513

10.1091/mbc.10.9.2933

10.1016/S0014-5793(00)01936-0

10.1091/mbc.E02-05-0292

10.1083/jcb.200206109

10.1242/dev.128.13.2485

Matsuda A, 1999, Corneal wound healing in tenascin knockout mouse, Invest Ophthalmol Vis Sci, 40, 1071

10.1046/j.1523-1747.1998.00401.x

Nakao N, 1998, Tenascin‐C promotes healing of Habu‐snake venom‐induced glomerulonephritis: studies in knockout congenic mice and in culture, Am J Pathol, 152, 1237

10.1083/jcb.107.6.2757

Schalkwijk J, 1991, Tenascin expression in human dermis is related to epidermal proliferation, Am J Pathol, 139, 1143

10.1034/j.1600-0781.2000.160401.x

10.1006/excr.1996.0014

10.1159/000211446

10.2307/3579787

10.1046/j.1523-1747.1999.00802.x

10.1007/s004030050200

10.1111/j.1365-2133.1994.tb13102.x

10.1111/j.1365-2133.1991.tb03276.x

10.1016/S0923-1811(96)00570-1

10.1111/j.1365-2133.1995.tb02486.x

10.1186/1471-2121-3-13

10.1164/ajrccm.154.2.8756830

10.1164/ajrccm.162.6.9912001

10.1164/ajrccm.156.3.9610084

10.1164/ajrccm.161.6.9907025

10.1136/thorax.58.2.135

10.1152/ajplung.1998.274.6.L1049

10.1016/0003-9969(95)00071-V

10.1007/s003840100312

10.1002/ijc.2910610402

Masaki T, 1998, Tenascin expression may reflect the activity and chronicity of human IgA nephropathy, Clin Nephrol, 50, 205

10.1016/S0344-0338(99)80113-7

10.1002/path.1131

10.1161/01.CIR.99.10.1284

10.2174/1566524024605699

10.4049/jimmunol.169.8.4604

10.1002/j.1460-2075.1988.tb03160.x

10.1006/dbio.1996.0266

10.1016/S8756-3282(97)00297-4

Offner FA, 1996, Transforming growth factor‐beta synthesis by human peritoneal mesothelial cells: induction by interleukin‐1, Am J Pathol, 148, 1679

10.1242/jcs.107.2.487

10.1111/1523-1747.ep12331160

10.1016/S0945-053X(98)90083-X

10.1002/path.1214

10.1002/art.1780351011

10.1016/S1359-6101(02)00026-6

10.1073/pnas.86.19.7437

10.4049/jimmunol.166.12.7534

10.1128/MCB.17.6.3202

10.1038/sj.onc.1203360

10.1161/hh1401.093582

10.1016/S0945-053X(99)00039-6

10.1097/00003086-199810001-00006

10.1083/jcb.124.4.401

10.1016/0007-1226(91)90008-8

10.1016/S0002-9440(10)65482-X

10.1359/jbmr.1997.12.1.52

10.1046/j.1365-2133.1999.02920.x

Mackie EJ, 1994, Tenascin in connective tissue development and pathogenesis, Perspect Dev Neurobiol, 2, 125

10.1111/j.1749-6632.2001.tb03931.x

Mackie EJ, 1992, Expression of tenascin by vascular smooth muscle cells: alterations in hypertensive rats and stimulation by angiotensin II, Am J Pathol, 141, 377

10.1242/jcs.112.18.3157

Martin JA, 2003, The role of tenascin‐C in adaptation of tendons to compressive loading, Biorheology, 40, 321

10.1242/jcs.113.20.3583

10.1152/ajpregu.00060.2002

10.1002/jor.1100180312

10.1016/0014-5793(93)80006-G

10.1078/0171-9335-00181

10.1006/excr.1998.4363

10.1083/jcb.127.6.2093

10.1016/S0945-053X(03)00004-0

10.1083/jcb.117.1.73

10.1074/jbc.274.31.21840

10.1002/ijc.10233

10.1016/S0022-510X(00)00347-6

Zagzag D, 2002, Angiogenesis in the central nervous system: a role for vascular endothelial growth factor/vascular permeability factor and tenascin‐C. Common molecular effectors in cerebral neoplastic and non‐neoplastic ‘angiogenic diseases’, Histol Histopathol, 17, 301

10.1016/S0090-3019(00)00307-4

10.1007/BF03032361

10.1097/00006123-199711000-00007

Zagzag D, 1996, Tenascin‐C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro, Cancer Res, 56, 182

10.1016/S0959-8049(02)00210-1

Adams M, 2002, Changes in tenascin‐C isoform expression in invasive and preinvasive breast disease, Cancer Res, 62, 3289

10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V

10.1002/(SICI)1097-0215(19961220)69:6<445::AID-IJC4>3.0.CO;2-4

Howeedy AA, 1990, Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast, Lab Invest, 63, 798

10.1016/S0959-8049(02)00210-1

10.1016/S0959-8049(98)00215-9

Ishihara A, 1995, Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance, Clin Cancer Res, 1, 1035

10.1002/ijc.10546

10.1038/bjc.1996.480

10.1006/gyno.1999.5405

10.1002/path.1258

Xue Y, 1998, Tenascin‐C expression in prostatic intraepithelial neoplasia (PIN): a marker of progression?, Anticancer Res, 18, 2679

10.1002/1097-0142(20010915)92:6<1419::AID-CNCR1465>3.0.CO;2-J

10.1002/(SICI)1097-0215(19990812)82:4<477::AID-IJC2>3.0.CO;2-5

Riedl S, 1997, Tenascin‐C tissue concentration in inflammatory and neoplastic diseases of the colon mucosa, Anticancer Res, 17, 3165

10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4

Sugawara I, 1991, Reduced tenascin expression in colonic carcinoma with lymphogenous metastasis, Invas Metast, 11, 325

10.1002/(SICI)1096-9098(199702)64:2<98::AID-JSO2>3.0.CO;2-J

10.1016/S1368-8375(01)00062-8

Zidar N, 2001, Expression of tenascin and fibronectin in benign epithelial hyperplastic lesions and squamous carcinoma of the larynx, Anticancer Res, 21, 451

10.1097/00005537-200001000-00016

10.1002/(SICI)1096-9896(199912)189:4<475::AID-PATH462>3.0.CO;2-V

Cai M, 2002, Degradation of tenascin‐C and activity of matrix metalloproteinase‐2 are associated with tumor recurrence in early stage non‐small cell lung cancer, Clin Cancer Res, 8, 1152

10.1038/sj.onc.1205726

10.1093/ajcp/100.2.145

10.1002/hep.510240525

10.1002/path.1214

10.1002/ijc.2910630324

10.1111/j.1600-0560.1994.tb00284.x

10.1111/j.1365-2559.1994.tb01268.x

Tanaka M, 2000, Clinical significance of tenascin‐C expression in osteosarcoma: tenascin‐C promotes distant metastases of osteosarcoma, Int J Mol Med, 5, 505

10.1016/0046-8177(95)90004-7

10.1002/(SICI)1097-0215(19970717)72:2<217::AID-IJC3>3.0.CO;2-U

10.3109/10428199609054786

10.1038/bjc.1998.15

10.1093/nar/21.1.163

Leprini A, 1994, Tenascin isoforms: possible targets for diagnosis and therapy of cancer and mechanisms regulating their expression, Perspect Dev Neurobiol, 2, 117

10.1046/j.1432-0436.1997.6220071.x

Adams M, 2002, Changes in tenascin‐C isoform expression in invasive and preinvasive breast disease, Cancer Res, 62, 3289

10.1002/ijc.2910520504

10.1097/00006123-200204000-00028

10.1016/S0002-9440(10)65388-6

10.1002/(SICI)1096-9896(199912)189:4<475::AID-PATH462>3.0.CO;2-V

10.1002/(SICI)1097-0215(19970717)72:2<236::AID-IJC6>3.0.CO;2-S

10.1002/(SICI)1097-0215(19990812)82:4<477::AID-IJC2>3.0.CO;2-5

10.1159/000055338

10.1097/00004424-199306000-00003

10.1007/BF01052668

Brown MT, 1996, Intrathecal 131I‐labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results, Clin Cancer Res, 2, 963

10.1200/JCO.1998.16.6.2202

10.1080/028418699431438

10.1200/JCO.2002.20.5.1389

10.1002/(SICI)1097-0215(19970529)71:5<810::AID-IJC19>3.0.CO;2-B

10.1007/s002590050397

Riva P, 1999, Loco‐regional radioimmunotherapy of high‐grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study, Clin Cancer Res, 5, 3275s

10.2174/1381612003399275

10.1074/jbc.M104651200